Alan Colowick

Naryx Pharma, Inc. developd products for the treatment of chronic sinusitis. Its products were focused on inhaled, nebulizer, intranasal drug formulations. Its products include Sybryx, which is used for the treatment of chronic sinusitis. The company focused on development of inhaled, nebulized, and intranasal drug formulations. The company was founded in 1999 and was headquartered in Carpinteria, CA.

Founded in 2010, Celgene International SARL is a Swiss bio-pharmaceutical company that operates to discover, develop, and commercialize therapies for unmet medical needs in cancer. Part of Bristol Myers Squibb Co., the company is based in Boudry, Switzerland.

Principia Biopharma, Inc. is a biopharmaceutical company, which engages in designing and developing oral therapies to patients with significant unmet medical needs in immunology and oncology. It operates through Tailored Covalency platform, which enables to develop small molecule inhibitors of enzymes and receptor ligands with potencies and selectivities that rival those of injectable biologics, yet maintain the convenience of a pill. Its product pipeline includes PRN1008, PRN2246, PRN1371, and immunoproteasome inhibitor. The company was founded by Jack Taunton and Richard A. Miller on October 6, 2008 and is headquartered in South San Francisco, CA.

Sofinnova Investment Inc (Sofinnova Investment) is a venture capital firm founded in 1976 by Jacques F. vallle & Joel F. Martin. The firm is headquartered in Menlo Park, California.

Nora Therapeutics, Inc. develops therapeutics to address clinical unmet needs in reproductive medicine. Its's lead product NT100, seeks to improve pregnancy outcomes in women undergoing in vitro fertilization or who have suffered recurrent spontaneous miscarriages. The company was founded by Darryl L. Carter and Chris B. McClain in 2007 and is headquartered in Palo Alto, CA.

Inventages II invests in companies located in Bahamas. The fund focus on companies such as life science and consumer applications. It provides financing for seed, early and buyout capital requirements.

InCarda Therapeutics, Inc. develops cardiovascular disease treatment through pulmonary delivery of established drugs. It also develops an inhaled therapy intended to treat paroxysmal atrial fibrillation. The company was founded by Narasimhan Rangachari, John S. Patton, Gregory M. Marcus and Carlos A. Schuler in 2009 and is headquartered in Newark, CA.

Dimension Therapeutics, Inc. engages in the development of novel treatments for rare diseases. Its activities include discoveries and development of therapeutic products for people living with rare diseases associated wit the liver and caused by genetic mutations. The company was founded by Ben Auspitz in June 20, 2013 and is headquartered in Cambridge, MA.

Human Longevity, Inc. provides precision health analytics to individuals through the Health Nucleus. The Health Nucleus is an assessment of current and future risk for cardiac, oncologic, metabolic and cognitive diseases and conditions. The firm offers database of sequenced genomes and phenotypic data. The company was founded by J. Craig Venter, Robert Joseph Hariri Gordon, and Peter H. Diamandis in 2013 and is headquartered in San Diego, CA.

Harpoon Therapeutics, Inc. is a clinical-stage immunotherapy company, which engages in the development of antibodies. It focuses on the research of novel class of T cell engagers that harness the power of the body’s immune system to treat patients suffering from cancer and other diseases. The firm utilizes its proprietary Tri-specific T cell Activating Construct platform to create a pipeline of novel TriTACs for the treatment of solid tumors and hematologic malignancies. The company was founded by Patrick A. Baeuerle, Luke B. Evnin, and Jeanmarie Guenot on March 19, 2015 and is headquartered in South San Francisco, CA.

Xylocor Therapeutics, Inc. engages in the biopharmaceutical company that develops gene therapy for people with advanced coronary artery disease. It focuses on developing product for patients with refractory angina with no treatment options and its secondary product for patients with cardiac tissue damage from heart attacks. The company was founded by Ronald Crystal and Todd Rosengart in 2013 and is headquartered in Malvern, PA.

ReCode Therapeutics, Inc. operates as a biopharmaceutical company. It develops precision medicines for pulmonary diseases. The company is headquartered in Irvin, TX.

VelosBio, Inc. operates as an biopharmaceutical company. It developes antibody-drug conjugates to treat hematological cancers and solid tumors. The company was founded in 2017 and is headquartered in San Diego, CA.

Teon Therapeutics, Inc. operates as a pharmaceutical company. It focuses on cancer immunotherapy. The company was founded by Yao Lina, Fan Peidong, Elfaith Elzein, and Liiu Jiwen in March 2018 and is headquartered in Redwood City, CA.

Anumana, Inc. is an AI-driven health technology company that leverages cutting-edge AI and industry-leading translational science to unlock the electrical language of the heart. The company is based in Cambridge, MA, and has subsidiaries in the United States. Anumana's software-as-a-medical device (SAMd) solutions aim to detect hidden diseases using ECG-AI algorithms to enhance and improve care through real-time AI insights. The company was founded in 2021 by nference and Mayo Clinic to develop innovative AI technology applied to ECG, electrophysiology, and hemodynamics. The CEO is Murali Aravamudan.

Alumis, Inc. is a precision medicines company called Esker that aims to provide personalized treatments for people with autoimmune diseases. The company is based in San Francisco, CA. Esker uses a precision analytics platform, powered by foresite labs, and a team of experts with deep experience in precision medicine drug discovery, development, and immunology to create medicines that change the lives of people with autoimmune disease. The company was founded by June H Lee. Martin Babler has been the CEO of the company since 2021.

Solve Therapeutics, Inc. is an oncology-focused biopharmaceutical company that develops novel antibody-based therapies targeting tumor-specific antigens. The company is based in Belmont, CA, and has subsidiaries in the United States. The company's formation has reunited members of the former VelosBio Inc. team, a highly experienced group with a proven ability to rapidly advance innovative therapeutics that address unmet medical needs in the treatment of cancer. Solvetx has been actively pursuing discovery and development efforts at its state-of-the-art laboratory facilities. The company has licensed or generated targeting antibodies and nanobodies with ideal characteristics to serve as the backbones for antibody-based therapeutics and has rights to technology supporting the development of diagnostic and therapeutic antibody-radionuclide conjugates (ARCs). Solvetx is supported by a syndicate of sophisticated healthcare investors, including Ayurmaya Capital Management Fund (an affiliate of Matrix Capital Management), Decheng Capital, General, and Surveyor Capital (a Citadel company). The company was founded by David M. Johnson and has been led by him as the CEO since incorporation.